Research · Sep 3, 2026
[NEU] NewMarket Corporation Thesis 2026: Petroleum Additives Cash Engine Plus the AMPAC Rocket-Oxidizer Bet
NewMarket Corporation (NYSE: NEU) is a US specialty-chemicals holding company headquartered in Richmond, Virginia, formed in 2004 from the Ethyl/Albemarle/Afton lineage as the parent of Afton Chemical (petroleum additives) and Ethyl Corporation (a small legacy/services business), and in 2024 it acquired AMPAC (American Pacific Corporation), creating a new Specialty Materials segment. NEU enters FY2026 with FY2025 revenue ~$2.7-3.1B (~flat to +6% YoY off ~$2.78B FY2024) and adj. EPS ~$28-36, reflecting ~$2.5-2.8B aggregate Petroleum Additives revenue plus ~$0.15-0.30B aggregate Specialty Materials (AMPAC) revenue plus a small Ethyl Corp contribution, all under President + CEO Thomas E. Gottwald (CEO since ~2004, ~20+ year tenure; the Gottwald family — a multi-generational industrial family, Ethyl/Albemarle lineage — holds controlling/closely-held ownership; he is the architect of the disciplined high-return petroleum-additives focus, the steady-capital-return model and the AMPAC diversification). The first thesis pillar is the Afton Chemical Petroleum Additives pipeline (~$2.5-2.8B revenue, ~85-92% revenue mix): lubricant additives — engine oil additives (the largest category — packages for passenger-car, heavy-duty and marine engine oils), driveline additives (transmission fluids, gear oils, axle fluids) and industrial-lubricant additives (hydraulic fluids, greases, metalworking, turbine oils) — plus fuel additives (gasoline and diesel detergents, cetane improvers, deposit-control, cold-flow); the petroleum-additives market is ~$15-18B+ globally and a tight oligopoly where ~4 players (Lubrizol/Berkshire, Infineum/ExxonMobil-Shell JV, Afton/NewMarket as the #3-4, Chevron Oronite/Chevron) control most of it, protected by high barriers — long OEM/engine-builder approval cycles, deep R&D and sticky customer specs — with customers the major oil companies, national oil companies and independent blenders, and the business carries high returns on capital, low capital intensity and strong free cash flow; FY2025 dynamics were flat-to-modest volume with raw-material costs (base oils, intermediates) normalizing as a margin tailwind after 2022-2024 inflation and oligopoly pricing discipline holding price/mix, lifting Afton's adj. operating margin toward ~14-18%+, and FY2026 catalyst is ~$2.5-2.9B revenue with continued raw-material relief, pricing discipline, the EV e-fluids/thermal-management opportunity (a small but growing offset to the slow secular EV headwind on engine-oil volumes) and margin toward ~15-19%+. The second pillar is the AMPAC Ammonium Perchlorate + Specialty Chemicals pipeline (~$0.15-0.30B revenue, ~5-10% revenue mix and growing): AMPAC is essentially the only North American producer at scale of ammonium perchlorate (AP) — the oxidizer in solid rocket-motor propellant (the Cedar City, Utah plant) — a true sole-source, strategic-asset franchise essential to US tactical and strategic missiles, missile-defense interceptors and solid-rocket-boosted launch, with effectively no domestic alternative; customers are the prime defense contractors and propulsion houses (Northrop Grumman, L3Harris/Aerojet Rocketdyne) and NASA, plus other specialty chemicals (sodium azide for airbag inflators, perchlorate derivatives, fine chemicals); the defense-spending, missile-replenishment, missile-defense and hypersonics tailwind has surged US and allied demand for tactical missiles (Javelin, Stinger, GMLRS, PAC-3, SM-3/6, NASAMS and more), every solid rocket motor needs AP, and AMPAC is capacity-constrained with multi-year backlogs and higher margins (~25-40%+); FY2025 brought the acquisition close and integration, strong (sold-out) demand, capacity-expansion/debottlenecking capex and long-term supply agreements, and FY2026 catalyst is ~$0.20-0.40B+ revenue on capacity ramp plus supply-agreement price resets materially higher plus hypersonics and next-gen-missile programs, with EBITDA growth and a potential sum-of-the-parts re-rating. The capital story: a ~$10.20-12.00 aggregate annual dividend per share (~1.7-2.5% yield; quarterly ~$2.55+ plus periodic special dividends historically; ~25-35% payout — low, with the rest going to buybacks and M&A), consistent buybacks (~$0.1-0.4B annual — the per-share-compounding lever, with a large share of the float retired over time), ~$0.5-1.5B net debt (modest; the 2024 AMPAC deal added some, deleveraging rapidly on free cash flow), ~0.5-1.5x net debt/EBITDA (low leverage), an investment-grade-equivalent credit profile and ~9-10M diluted shares (very low — the Gottwald family controls a large block; declining on buybacks). At ~$500-700 per share on ~9-10M shares (~$5-7B equity, ~$6-8B EV) NEU trades at ~13-20x P/E, ~9-14x EV/EBITDA and ~2-3x P/Sales versus specialty-chemicals comps Innospec, Croda, Element Solutions, Quaker Houghton, Stepan and Balchem and defense-materials/moat-business comps Cadre Holdings, Mercury Systems, Heico and TransDigm. FY2026 base case is ~$2.7-3.1B revenue + ~$30-40 adj. EPS + ~$0.6-0.85B adj. EBITDA + ~0.5-1.0x net debt/EBITDA; bull case ~$2.9-3.4B revenue + ~$38-50 adj. EPS on Afton raw-material normalization and pricing discipline plus EV e-fluids, AMPAC capacity expansion completing with supply-agreement price resets meaningfully higher amid the missile-replenishment/missile-defense/hypersonics surge (AMPAC revenue toward ~$0.4-0.6B+ at ~30-40%+ margin) plus a sum-of-the-parts re-rating, buybacks and a delevered balance sheet; bear case ~$2.6-2.8B revenue + ~$24-32 adj. EPS on oligopoly pricing breaking down, a faster-than-expected EV headwind, a raw-material-cost spike, weak global industrial activity, AMPAC capacity-expansion delays or a defense-budget downturn, AMPAC safety/environmental/regulatory incidents, customer-concentration risk and Gottwald-family-control/minority considerations. The thesis depends on the Afton Chemical Petroleum Additives pipeline plus the AMPAC Ammonium Perchlorate + Specialty Chemicals pipeline plus the global petroleum-additives oligopoly position plus sticky OEM-approved specs plus raw-material-cost normalization plus the sole-source North American ammonium-perchlorate franchise plus the defense/missile tailwind plus capacity expansion plus the low dividend payout plus consistent buybacks plus the low share count plus low leverage and Thomas Gottwald's disciplined-capital-return and AMPAC-integration execution.